Anti-CD20 Therapies for MS
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.
EP: 1.Multiple Sclerosis Disease Course and Classification
EP: 2.Defining the Utility of PIRA in Practice
EP: 3.Addressing Inflammation Upon the Diagnosis of MS
EP: 4.Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches
EP: 5.Shared Decision-Making in Multiple Sclerosis Treatment
EP: 6.Clinical Trial Design and Personalized Medicine in Multiple Sclerosis
EP: 7.Customizing Treatment Approaches With High Efficacy Therapies
EP: 8.When to Stop Multiple Sclerosis Therapy
EP: 9.Immunological Phenotypes of Multiple Sclerosis and Patient Race
EP: 10.Pregnancy and Lactation in Multiple Sclerosis
EP: 11.Bladder Management and Patient-Reported Outcomes in Multiple Sclerosis Management
EP: 12.The Importance of Lifestyle Changes in Multiple Sclerosis Care
EP: 13.Anti-CD20 Therapies for MS
EP: 14.Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies
EP: 15.Safety of Anti-CD20 Therapies in Multiple Sclerosis
EP: 16.Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.
The discussion revolves around NTCD-20s, a class of medications used in treating multiple sclerosis (MS). An expert outlines several options within this class, including rituximab, ocrelizumab, ofatumumab, and ublituxumab. These medications have differences in administration methods, target binding on the CD20 molecule, and mechanisms of action in lysing B cells.
Despite these variances, all NTCD-20s effectively control MS by removing CD20-positive B cells from circulation. Factors like infusion duration, pre-medication needs, and risk of infusion reactions vary between medications. Notably, infused medications tend to have longer B cell depletion durations compared to subcutaneously administered versions.
The conversation emphasizes that NTCD-20s offer high efficacy with manageable risks, even for patients of childbearing age. The speaker highlights the shift in treatment patterns towards using these medications early in MS management, citing ongoing pragmatic trials that validate clinical practice.
The discussion extends to patient candidacy, with NTCD-20s being considered suitable for most MS patients. Notably, women of childbearing age benefit from medications allowing intermittent dosing, facilitating family planning while effectively treating the disease.
Additionally, the importance of medication adherence and monitoring is stressed, with a recognition of the art of medicine in tailoring treatment approaches to individual patient needs, despite regulatory guidelines. Overall, the dialogue underscores the efficacy and adaptability of NTCD-20s in MS management, reflecting a nuanced understanding of both medical science and patient care.
Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.
